Symbols

ABSI

Absci·NASDAQ

--(--)

ABSI fundamentals

ABSI Q4 2025 Earnings

Absci (ABSI) released its earnings on Mar 24, 2026: revenue was 650.00K (YoY -2.26%), missed estimates; EPS was -0.2 (YoY +20.00%), missed estimates.

Revenue / YoY

650.00K

-2.26%

EPS / YoY

-0.2

+20.00%

Report date

Mar 24, 2026

ABSI Earnings Call Summary for Q4,2025

ABS-201 Clinical Momentum: Dosed first 3 SAD cohorts in AGA trial with favorable safety; 13-week POC data expected H2 2026. Expanded into endometriosis with potential for disease-modifying therapy.
AI Platform Differentiation: Published first de novo antibody design with 0 prior epitopes; Origin-1 generates <100 designs per target vs. industry standards.
Financial Strength: $144M cash runway into 2028; R&D expenses up 37% to $25.3M to fund clinical trials.
Market Opportunity: $25B+ AGA addressable market; $10B+ endometriosis opportunity with no FDA-approved disease-modifying therapies.

Earnings

EPS

Revenue

Revenue & Expenses

ABSI has released its 2025 Q4 earnings report, with revenue of 650.00K, reflecting a YoY change of -2.26%, and net profit of -29.56M, showing a YoY change of -2.00%. The Sankey diagram below clearly presents ABSI's revenue sources and cost distribution.

Key Indicators

Absci (ABSI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Absci (ABSI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Absci (ABSI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Absci (ABSI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown